Innovative and cost-effective preclinical (nonclinical) CRO services focusing on cardiovascular (infarct size, heart failure, sepsis, stroke etc.), metabolic (diabetes, hyperlipidemia, atherosclerosis, obesity etc.), renal, inflammation, and neuropathy diseases.
Cardiovascular Technology platform from cells to large animals including farm pigs and minipigs (e.g. Göttingen minipigs) models of cardiovascular diseases is under continuous development.
Different diet, toxin, genetic induced metabolic models including diabetes, metabolic disease, hyperlipidemia, atherosclerosis, obesity, uremia.
Clinical R&D services focusing on clinical trials with medical devices, combination products (biologics + medical devices), managing Investigator Initiated Trials, and niche trials that need sensitive patient population, therefore, strong scientific and regulatory support.
Pharmahungary Group is uniquely positioned on medical device/drug/biologics combination clinical trial services. Full CRO service in consulting and conducting: feasibility studies, regulatory and ethics committee submission, monitoring, site management, contract management from study start-up to closure.
Since 2010 the preclinical and clinical staff of Pharmahungary Group have been working together with manufacturers and research professionals to develop new collaboration structures in this cutting edge field. Explore the benefits of Investigator Initiated Trials!
Pharmahungary manages internal preclinical (nonclinical) R&D projects to develop new technologies in the fields of diagnosis and therapy of cardiovascular diseases. Some projects are open for out-licensing, co-development, and investment.
Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and anti-ischemic effect.
Novel structure small molecules for selective inhibition of MMP 2, 9, 13, and their application for ischemic (e.g. heart) diseases.
Several cytoprotective miRNA targets, termed "ProtectomiR".
Clinical Director attended conference of Hungarian Competent Authority, National Institute of Pharmacy and Nutrition on current challenges of the pharmaceutical industry